Background and objectives: Malignant hyperthermia (MH) is a pharmacogenetic skeletal muscle disorder characterized by a hypermetabolic state after anesthesia with succinylcholine and/ or volatile anesthetics. Various neuromuscular syndromes are associated with susceptibility; however, Moebius syndrome has not been reported. Dantrolene is the drug of choice for treatment. Recurrence may occur in up to 20 % of cases after the initial event treatment. Case Report: Male infant, fi rst twin, 7 months old, weighing 6.5 kg and presenting with Moebius syndrome was admitted for clubfoot repair. The patient had MH after exposure to sevofl urane and succinylcholine, which was readily reversed with dantrolene maintained for 24 hours. Ten hours after da...
Malignant hyperthermia (MH) is a rare and life-threatening pharmacogenetic disorder triggered by vol...
Malignant hyperthermia manifests clinically as a hypermetabolic crisis when a malignant hyperthermia...
Malignant hyperthermia (MH) can develop after contact with volatile anesthetics (halothane, enfluran...
Background and objectives: Malignant hyperthermia (MH) is a pharmacogenetic skeletal muscle disorder...
Background and objectives: Malignant hyperthermia (MH) is a pharmacogenetic skeletal muscle disorder...
AbstractBackground and objectivesMalignant hyperthermia (MH) is a pharmacogenetic skeletal muscle di...
Malignant hyperthermia (MH) is a genetic syndrome characterized by hyperthermia, tachycardia, acidos...
MALIGNANT hyperthermia (MH) is a rare autoso-mal dominant genetic disorder of the skeletal mus-cle, ...
PURPOSE: The present report of two fatal awake malignant hyperthermia (MH) episodes in an MH suscept...
Background Malignant hyperthermia (MH), a metabolic myopathy triggered by volatile anesthetics an...
Malignant hyperthermia (MH) is a rare hypermetabolic disorder of skeletal muscles that manifests as ...
Malignant hyperthermia is a rare pharmacogenetic disorder triggered by depolarizing muscle relaxant ...
Malignant Hyperthermia (MH), is a rare emergency that happened during General Anesthesia. In Albania...
Background: Malignant hyperthermia (MH) is a rare pharmacogenetic disorder which is characterized by...
Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile an...
Malignant hyperthermia (MH) is a rare and life-threatening pharmacogenetic disorder triggered by vol...
Malignant hyperthermia manifests clinically as a hypermetabolic crisis when a malignant hyperthermia...
Malignant hyperthermia (MH) can develop after contact with volatile anesthetics (halothane, enfluran...
Background and objectives: Malignant hyperthermia (MH) is a pharmacogenetic skeletal muscle disorder...
Background and objectives: Malignant hyperthermia (MH) is a pharmacogenetic skeletal muscle disorder...
AbstractBackground and objectivesMalignant hyperthermia (MH) is a pharmacogenetic skeletal muscle di...
Malignant hyperthermia (MH) is a genetic syndrome characterized by hyperthermia, tachycardia, acidos...
MALIGNANT hyperthermia (MH) is a rare autoso-mal dominant genetic disorder of the skeletal mus-cle, ...
PURPOSE: The present report of two fatal awake malignant hyperthermia (MH) episodes in an MH suscept...
Background Malignant hyperthermia (MH), a metabolic myopathy triggered by volatile anesthetics an...
Malignant hyperthermia (MH) is a rare hypermetabolic disorder of skeletal muscles that manifests as ...
Malignant hyperthermia is a rare pharmacogenetic disorder triggered by depolarizing muscle relaxant ...
Malignant Hyperthermia (MH), is a rare emergency that happened during General Anesthesia. In Albania...
Background: Malignant hyperthermia (MH) is a rare pharmacogenetic disorder which is characterized by...
Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile an...
Malignant hyperthermia (MH) is a rare and life-threatening pharmacogenetic disorder triggered by vol...
Malignant hyperthermia manifests clinically as a hypermetabolic crisis when a malignant hyperthermia...
Malignant hyperthermia (MH) can develop after contact with volatile anesthetics (halothane, enfluran...